Five hospitals in England and Wales have switched to urine test, rather than invasive hospital procedure ...

A new noninvasive test may be able to detect bladder cancer recurrence earlier than standard cytology and cystoscopy, according to new findings published online July 7 in the British Journal of Cancer ...

Marks the first Medicare coverage decision for Veracyte’s whole-genome sequencing-based TrueMRD platform and launch of the first test Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics ...

In a multi-institutional study published in the European Urology journal, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at higher ...

Bladder cancer arises from the lining of the bladder, the organ that stores urine, and is one of the most common cancers in the United States. Most patients are diagnosed at an early stage called ...

Cellens, a Boston, MA-based cancer diagnostics startup, has raised a $6.5 million seed round. The company is developing a mechanobiology and AI-driven platform, BioFeel, for non-invasive cancer ...

Speculation swirled for weeks around the health of Deion Sanders, Colorado Buffaloes head coach and famed Pro Football Hall of Fame inductee, who had been notably absent from team practice. Limited ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...